New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue ...

of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin ...

SHANGHAI, China I May 9, 2025 I Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing ...

BALLERUP, Denmark I May 09, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with ...

Study will evaluate OX-4224 as a second-line monotherapy in patients with PD-L1–positive non-small cell lung cancer, expanding potential access to checkpoint ...

SAN DIEGO, CA, USA I May 5, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development ...

– ABO21009’s unique mechanism of action depletes pathogenic T and B cells, induces expansion of Tregs for lasting efficacy, and preserves overall immunity- GOSSELIES, Belgium and NANTES, France I May ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation ...

PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application ...